The primary objective of this project is to support the advanced development of candidate products which consist of a vaccine component in combination with a technology component (a dry formulation technology) to increase stability and minimize cold chain or preservative requirements for use in post-event settings following the intentional release of or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B, and C Priority Pathogens.

Project Start
2014-09-10
Project End
2024-01-05
Budget Start
Budget End
Support Year
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Pharmathene, Inc.
Department
Type
DUNS #
082804936
City
Annapolis
State
MD
Country
United States
Zip Code
21401